주요 내용으로 건너 뛰기

Fierce Pharma – IRA biosimilar measure intended to boost uptake so far has ‘limited’ impact: report

Check out this article in Fierce Pharma to learn how Certara’s US Market Access team performed original research to quantify the impact of the Inflation Reduction Act (IRA) on uptake of biosimilars for oncology. The IRA, passed two years ago, included a provision to incentivize providers to use biosimilars and save billions for the U.S. healthcare system. In their research report, Certara experts surveyed oncology staff at 79 healthcare facilities on their use of 17 biosimilar products. The findings indicate that the IRA’s impact has been limited with the next three years being the real test of the legislation.

Powered by Translations.com GlobalLink Web Software